Skip to main content

Cannabix Technologies Delivers First Breath-Based DOT-Like Multi-Drug Testing Panel for Recent-Use Detection

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”), a developer of marijuana and alcohol breath testing technologies is pleased to announce that it has made first commercial delivery of its new breath-based multi-drug test panel. The panel is modeled after the drug classes included in the U.S. Department of Transportation’s (DOT) federally mandated urine drug testing program, including amphetamines/methamphetamines, cocaine, marijuana (THC), opiates, and phencyclidine (PCP) (the “DOT-like Panel”).

This first deployment follows the validation by Omega Laboratories, Inc. of a laboratory developed test method utilizing the Cannabix Breath Collection Unit (“BCU”) and Breath Cartridge technologies. The validated method supports the simultaneous detection of multiple drug classes from breath samples, expanding Cannabix’s breath testing capabilities beyond cannabinoids and demonstrating the versatility of its technology.

Figure 1. Cannabix Technologies Inc. Breath Collection Unit (BCU) picture

Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.

Unlike urine and hair testing, which can identify historical drug exposure over days, weeks, or months, employers and other decision-makers are often seeking information about more recent drug use. Breath testing is intended to target a substantially shorter detection window following drug consumption. Cannabix’s breath-testing technology is designed to help address this gap by focusing on a shorter detection period, ranging from 15 minutes to 4 hours after use, which provides a more relevant time window in safety-sensitive situations. By combining observed breath collection, chain-of-custody procedures, split-sample capability, and laboratory mass spectrometry confirmation, the Company’s breath-based DOT-like testing model is designed to support drug testing programs where scientific rigor, evidentiary defensibility, and operational practicality are important requirements.

The Company’s new breath-based multi-drug test panel option expands Cannabix’s breath-testing platform beyond marijuana detection and is targeted toward workplace testing, criminal justice and treatment monitoring programs, post-incident investigations, reasonable-suspicion testing, and other safety-sensitive environments where recent-use assessment is a key objective.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in workplaces, law enforcement, and a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements may include, but are not limited to, statements regarding the development, validation, performance, commercialization, deployment, market acceptance, regulatory considerations, and potential applications of the Company’s breath-testing technologies, including its marijuana breath-testing programs, multi-drug breath-testing initiatives, Breath Collection Unit (“BCU”), Breath Cartridge technologies, and related products and services. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” and similar expressions. Forward-looking statements are based on management’s current expectations, assumptions, and beliefs as of the date of this news release. Actual results may differ materially from those expressed or implied by such forward-looking statements due to various risks and uncertainties, including but not limited to research and development outcomes, technology performance, validation results, regulatory developments, intellectual property protections, commercial adoption, industry acceptance, competitive factors, availability of financing, and general economic and market conditions. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4700246e-375c-410d-bf41-55faf39a9ef1

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.